Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...

Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to ...

AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Whether or not antipsychotic medication should be initiated depends upon the severity of the behavioral disturbance, the persistence of symptoms and whether the patient needs to be rechallenged ...

It followed a report by the Royal Commission, which in December 2022 found the survivors and victims of the Lake Alice child ...